Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer

BACKGROUND: The 2015 American Society of Clinical Oncology guidelines recommend first-line treatment of hormone receptor (HR)-positive breast cancer with endocrine therapy plus or minus palbociclib, a selective cyclin-dependent kinase (CDK)4/6 inhibitor. In 2018, the U.S. Food and Drug Administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Vivian, Zhong, Lixian, Narsipur, NihaL, Hays, Elizabeth, Tran, Daniel Khuong, Rosario, Kimberly, Wilson, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390904/
https://www.ncbi.nlm.nih.gov/pubmed/33645243
http://dx.doi.org/10.18553/jmcp.2021.27.3.327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390904/
https://www.ncbi.nlm.nih.gov/pubmed/33645243
http://dx.doi.org/10.18553/jmcp.2021.27.3.327

Ejemplares similares